Group items tagged

The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The diagnostics advisory committee, a standing advisory committee of NICE, agreed that it should be possible to gather samples for genotype testing at a location that is convenient for the person having the test and highlighted the role of pharmacies as accessible locations for CYP2C19 genotype testing.The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel use for patients who have suffered an ischemic stroke or transient ischemic attack. Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to guide prescribed antiplatelet medication. According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test results and recommending appropriate antiplatelet therapy. It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke patients. The d

Researchers from King's College London and the University of Helsinki have identified a link between periodontitis (gum disease) and cryptogenic ischemic stroke, which causes a blockage in the blood vessel supplying blood to a region of the brain. The findings, recently published in the Journal of Dental Research, emphasise severe gum disease as a risk factor for young-onset stroke, particularly in patients with no other identifiable risk factors. Dr. Susanna Paju, Periodontology Specialist from the University of Helsinki, led the study in collaboration with Dr. Svetislav Zaric, Clinical Lecturer in Periodontology from King's College London. Dr. Zaric explains the implications of their research: "Stroke remains the second leading cause of death globally. Strikingly, the incidence and prevalence of ischemic stroke have been increasing in the younger population during past decades," she said. "Periodontitis, which involves deep inflammation of the gums due to bacteria under the gumline, can lead to systemic effects as bacteria enter the bloodstream and affect other parts of the body," she added.

As per a new study, Inflammatory bowel disease can result into heart disease.

ischemic heart disease causes,symptoms and prevention treatment

Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes. Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION). To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of semaglutide-containing medicines after concerns were raised regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is used in the treatment of diabetes and obesity, with medicines like Ozempic, Rybelsus, and Wegovy containing the active substance. A report from the PRAC highlighted two recent observational studies that suggest patients treated with semaglutide may face a higher risk of developing NAION. This condition, caused by reduced blood flow to the optic nerve, can result in vision loss in the affected eye. However, two other recent observational studies did not show an increased risk, according to the report.

Stroke is a cerebrovascular syndrome that involves the blockage and bursting of blood vessels in the brain. It shows a multifactorial pattern of inheritance. High cholesterol levels, high blood pressure, hypertension and obesity are the key causes of stroke besides inherited genes.

Usage of Single Use Endoscopic Linear Cutter Reload Instruction for use The Single Use Endoscopic Stapler should not be used on tissue such as liver or spleen where compressibility would be destructive when closure of the instruments on it. Do not use the Single Use Endoscopic Stapler when hemostasis cannot be ensured. Do not use the Single Use Endoscopic Stapler on severe mucous edema, ischemic or necrotic tissue. The Single Use Endoscopic Stapler is provided STERILE and are intended to be used in a SINGLE procedure only.